Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: A meta-analysis

European Journal of Surgical Oncology

Volumn 40, Issue 7, 2014, Pages 794-804

  Rijkers, A P ^a   Valkema, R ^a   Duivenvoorden, H J ^a   Van Eijck, C H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Diagnostic imaging; Meta analysis; Pancreatic neoplasms; Positron emission tomography; Review

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CHRONIC PANCREATITIS; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; METHODOLOGY; OUTCOME ASSESSMENT; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SEARCH ENGINE; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

DIAGNOSTIC IMAGING; META-ANALYSIS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; REVIEW;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84901491136     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.03.016     Document Type: Review

References (92)

1. S. Raimondi, P. Maisonneuve, and A.B. Lowenfels Epidemiology of pancreatic cancer: an overview Nat Rev Gastroenterol Hepatol 6 12 2009 Dec 699 708
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J Clin 62 1 2012 Jan-Feb 10 29 [Comparative Study]
3. J.H. Klinkenbijl, J. Jeekel, and T. Sahmoud et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 6 1999 Dec 776 782 [discussion 82-4]
4. J.H. Klinkenbijl, J. Jeekel, and P.I. Schmitz et al. Carcinoma of the pancreas and periampullary region: palliation versus cure Br J Surg 80 12 1993 Dec 1575 1578
5. J.P. Neoptolemos, D.D. Stocken, and H. Friess et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 12 2004 Mar 18 1200 1210
6. H. Oettle, S. Post, and P. Neuhaus et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 3 2007 Jan 17 267 277 [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]
7. T.A. Sohn, C.J. Yeo, and J.L. Cameron et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 6 2000 Nov-Dec 567 579
8. M. Wagner, C. Redaelli, M. Lietz, C.A. Seiler, H. Friess, and M.W. Buchler Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma Br J Surg 91 5 2004 May 586 594 [Clinical Trial Randomized Controlled Trial]
9. M. Hidalgo Pancreatic cancer N Engl J Med 362 17 2010 Apr 29 1605 1617 [Review]
10. A. Sonnenberg, S.A. Rodriguez, and D.O. Faigel Diagnostic ascertainment of suspicious pancreatic mass: a threshold analysis Clin Gastroenterol Hepatol 6 10 2008 Oct 1162 1166
11. E.J. Nieveen van Dijkum, K.F. Kuhlmann, C.B. Terwee, H. Obertop, J.C. de Haes, and D.J. Gouma Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma Br J Surg 92 4 2005 Apr 471 477
12. S. Bipat, S.S. Phoa, and O.M. van Delden et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis J Comput Assist Tomogr 29 4 2005 Jul-Aug 438 445 [Comparative Study Meta-Analysis]
13. N.C. Buchs, L. Buhler, and P. Bucher et al. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study J Gastroenterol Hepatol 26 4 2011 Apr 657 662
14. B.B. Chin, and P.P. Chang Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography Best Pract Res Clin Gastroenterol 20 1 2006 Feb 3 21
15. R. Boellaard, M.J. O'Doherty, and W.A. Weber et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging 37 1 2010 Jan 181 200
16. F. Pakzad, A.M. Groves, and P.J. Ell The role of positron emission tomography in the management of pancreatic cancer Semin Nucl Med 36 3 2006 Jul 248 256 [Review]
17. S. Bang, H.W. Chung, and S.W. Park et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer J Clin Gastroenterol 40 10 2006 923 929
18. D. Delbeke, D.M. Rose, and W.C. Chapman et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma J Nucl Med 40 11 1999 1784 1791
19. A. Imdahl, E. Nitzsche, and F. Krautmann et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer Br J Surg 86 2 1999 194 199
20. J.C. Stollfuss, G. Glatting, H. Friess, F. Kocher, H.G. Berger, and S.N. Reske 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation Radiology 195 2 1995 May 339 344
21. G. Bond-Smith, N. Banga, T.M. Hammond, and C.J. Imber Pancreatic adenocarcinoma BMJ 344 2012 e2476 [Review]
22. J.A. Berlin Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group Lancet 350 9072 1997 Jul 19 185 186 [Clinical Trial Comparative Study Letter Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.]
23. P. Whiting, A.W. Rutjes, J.B. Reitsma, P.M. Bossuyt, and J. Kleijnen The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Med Res Methodol 10 3 2003 Nov 25 [Evaluation Studies Research Support, Non-U.S. Gov't]
24. J.B.R.A. Reitsma, P. Whiting, V.V. Vlassov, M.M.G. Leeflang, and J.J. Deeks Cochrane handbook for systematic reviews of diagnostic test accuracy version 1.0.0 J.J.B.P. Deeks, C. Gatsonis, Assessing methodological quality: the cochrane collaboration 2009 2009 [Chapter 9]
25. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 7414 2003 Sep 6 557 560 [Research Support, Non-U.S. Gov't Review]
26. R. Bares, P. Klever, and S. Hauptmann et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer Radiology 192 1 1994 79 86
27. C.G. Diederichs, L. Staib, and B. Glasbrenner et al. F-18 fluorodeoxyglucose (FDG) and C-Reactive Protein (CRP) Clin Positron Imaging 2 3 1999 May 131 136
28. M.C. Giorgi, R.M. Cunha, and J. Soares Jr. et al. Dual-head gamma camera coincidence imaging in pancreatic cancer Rev Esp Med Nucl 23 2 2004 Mar-Apr 90 94
29. C.L. Ho, F. Dehdashti, L.K. Griffeth, P.E. Buse, D.M. Balfe, and B.A. Siegel FDG-PET evaluation of indeterminate pancreatic masses J Comput Assist Tomogr 20 3 1996 363 369
30. T. Inokuma, N. Tamaki, and T. Torizuka et al. Evaluation of pancreatic tumors with positron emission tomography and F- 18 fluorodeoxyglucose: comparison with CT and US Radiology 195 2 1995 345 352
31. M.F. Kalady, B.M. Clary, and L.A. Clark et al. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms Ann Surg Oncol 9 8 2002 Oct 799 806
32. M.T. Keogan, D. Tyler, and L. Clark et al. Diagnosis of pancreatic carcinoma: role of FDG PET Am J Roentgenol 171 6 1998 1565 1570
33. K. Koyama, T. Okamura, and J. Kawabe et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions Ann Nucl Med 15 3 2001 Jun 217 224
34. A.J. Lemke, S.M. Niehues, and N. Hosten et al. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions - a prospective study with 104 patients J Nucl Med 45 8 2004 1279 1286
35. D. Lytras, S. Connor, and L. Bosonnet et al. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer Dig Surg 22 1-2 2005 55 61
36. H.R. Mertz, P. Sechopoulos, D. Delbeke, and S.D. Leach EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma Gastrointest Endosc 52 3 2000 Sep 367 371
37. Y. Nakamoto, T. Higashi, and H. Sakahara et al. Delayed 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas Cancer 89 12 2000 2547 2554
38. Y. Nishiyama, Y. Yamamoto, and T. Monden et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour Nucl Med Commun 26 10 2005 895 901
39. M. Papos, T. Takacs, and L. Tron et al. The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions Clin Nucl Med 27 3 2002 Mar 197 201
40. D.M. Rose, D. Delbeke, and R.D. Beauchamp et al. 18Fluorodeoxyglucose- positron emission tomography in the management of patients with suspected pancreatic cancer Ann Surg 229 5 1999 729 738
41. J. Ruf, E. Lopez Hanninen, and M. Bohmig et al. Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer Pancreatology 6 6 2006 512 519
42. M. Zimny, R. Bares, and J. Fass et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases Eur J Nucl Med 24 6 1997 678 682
43. S. Beliao, A. Ferreira, and I. Vierasu et al. MR imaging versus PET/CT for evaluation of pancreatic lesions Eur J Radiol 81 10 2012 Oct 2527 2532
44. J.M. Farma, A.A. Santillan, and M. Melis et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms Ann Surg Oncol 15 9 2008 Sep 2465 2471
45. S. Heinrich, G.W. Goerres, and M. Schafer et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness Ann Surg 242 2 2005 235 243
46. S.L. Hu, Z.Y. Yang, Z.R. Zhou, X.J. Yu, B. Ping, and Y.J. Zhang Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation Nucl Med Commun 34 6 2013 Jun 533 539
47. S.P. Kauhanen, G. Komar, and M.P. Seppanen et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer Ann Surg 250 6 2009 957 963
48. S. Santhosh, B.R. Mittal, and D. Bhasin et al. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics J Gastroenterol Hepatol 28 2 2013 Feb 255 261
49. V. Schick, C. Franzius, and T. Beyna et al. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound Eur J Nucl Med Mol Imaging 35 10 2008 1775 1785
50. J. Yao, G. Gan, and D. Farlow et al. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours ANZ J Surg 82 3 2012 Mar 140 144 [Evaluation Studies]
51. H. Friess, J. Langhans, and M. Ebert et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography Gut 36 5 1995 May 771 777
52. K. Herrmann, M. Erkan, and M. Dobritz et al. Comparison of 3'-deoxy-3'-[(1)(8)F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours Eur J Nucl Med Mol Imaging 39 5 2012 May 846 851 [Comparative Study]
53. I. Rasmussen, J. Sorensen, B. Langstrom, and U. Haglund Is positron emission tomography using 18F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses? Scand J Surg 93 3 2004 191 197
54. A. Sendler, N. Avril, and H. Helmberger et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F- fluorodeoxyglucose: diagnostic limitations World J Surg 24 9 2000 1121 1129
55. E. Singer, M. Gschwantler, and D. Plattner et al. Differential diagnosis of benign and malign pancreatic masses with 18F-fluordeoxyglucose-positron emission tomography recorded with a dual-head coincidence gamma camera Eur J Gastroenterol Hepatol 19 6 2007 471 478
56. M.C.A. Van Kouwen, J.B.M.J. Jansen, H. Van Goor, S. De Castro, W.J.G. Oyen, and J.P.H. Drenth FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis Eur J Nucl Med Mol Imaging 32 4 2005 399 404
57. E. Bombardieri, G. Aliberti, C. de Graaf, E. Pauwels, and F. Crippa Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer Semin Surg Oncol 20 2 2001 Mar 134 146
58. M. Westerterp, J. Pruim, and W. Oyen et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters Eur J Nucl Med Mol Imaging 34 3 2007 Mar 392 404
59. H. Benyounes, F.W. Smith, and C. Campbell et al. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma Nucl Med Commun 16 7 1995 Jul 575 580
60. M.M. Leeflang, J.J. Deeks, A.W. Rutjes, J.B. Reitsma, and P.M. Bossuyt Bivariate meta-analysis of predictive values of diagnostic tests can be an alternative to bivariate meta-analysis of sensitivity and specificity J Clin Epidemiol 65 10 2012 Oct 1088 1097 [Comparative Study Research Support, Non-U.S. Gov't]
61. J. Menke Bivariate random-effects meta-analysis of sensitivity and specificity with SAS PROC GLIMMIX Methods Inf Med 49 1 2010 54 62 -4
62. J.B. Reitsma, A.S. Glas, A.W. Rutjes, R.J. Scholten, P.M. Bossuyt, and A.H. Zwinderman Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews J Clin Epidemiol 58 10 2005 Oct 982 990 [Review]
63. H.C. van Houwelingen, L.R. Arends, and T. Stijnen Advanced methods in meta-analysis: multivariate approach and meta-regression Stat Med 21 4 2002 Feb 28 589 624 [Review]
64. E.B. Deerenberg, J.W. Poley, J.J. Hermans, S. Ganesh, E. van der Harst, and C.H. van Eijck Role of endoscopic ultrasonography in patients suspected of pancreatic cancer with negative helical MDCT scan Dig Surg 28 5-6 2011 398 403
65. A. Asagi, K. Ohta, and J. Nasu et al. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence Pancreas 42 1 2013 Jan 11 19 [Research Support, Non-U.S. Gov't]
66. H. Wakabayashi, Y. Nishiyama, and T. Otani et al. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer World J Gastroenterol 14 1 2008 64 69
67. K. Izuishi, Y. Yamamoto, T. Sano, R. Takebayashi, T. Masaki, and Y. Suzuki Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer J Gastrointest Surg 14 7 2010 1151 1158
68. K. Kitajima, K. Murakami, and E. Yamasaki et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT Mol Imaging Biol 12 4 2010 452 459
69. Y. Nishiyama, Y. Yamamoto, and K. Yokoe et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer Ann Nucl Med 19 6 2005 491 497
70. K. Strobel, S. Heinrich, and U. Bhure et al. Contrast-enhanced 18F-FDG PET/CT: 1-Stop-shop imaging for assessing the resectability of pancreatic cancer J Nucl Med 49 9 2008 1408 1413
71. Y. Nakamoto, T. Higashi, and H. Sakahara et al. Contribution of PET in the detection of liver metastases from pancreatic tumours Clin Radiol 54 4 1999 248 252
72. S. Heinrich, M. Schafer, and A. Weber et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity results of a prospective phase II trial Ann Surg 248 6 2008 1014 1021
73. M. Kuwatani, H. Kawakami, and K. Eto et al. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers Intern Med 48 11 2009 867 875
74. S.M. Lee, T.S. Kim, J.W. Lee, S.K. Kim, S.J. Park, and S.S. Han Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET Clin Nucl Med 36 5 2011 331 336
75. A. Lyshchik, T. Higashi, and Y. Nakamoto et al. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer Eur J Nucl Med Mol Imaging 32 4 2005 389 397
76. B. Nakata, S. Nishimura, and T. Ishikawa et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer Int J Oncol 19 1 2001 53 58
77. D. Schellenberg, A. Quon, and A.Y. Minn et al. 18Fluorodeoxyglucose pet is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy Int J Radiat Oncol Biol Phys 77 5 2010 1420 1425
78. C. Sperti, C. Pasquali, F. Chierichetti, A. Ferronato, G. Decet, and S. Pedrazzoli 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma J Gastrointest Surg 7 8 2003 953 960
79. K. Tanimoto, K. Yoshikawa, and T. Obata et al. Role of glucose metabolism and cellularity for tumor malignancy evaluation using FDG-PET/CT and MRI Nucl Med Commun 31 6 2010 604 609
80. M. Zimny, J. Fass, and R. Bares et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma Scand J Gastroenterol 35 8 2000 883 888
81. I.C. Hwang, Y.J. Kim, and K.H. Kim et al. Prognostic value of B-type natriuretic peptide in patients with chronic mitral regurgitation undergoing surgery: mid-term follow-up results Eur J Cardiothorac Surg 43 1 2013 Jan e1 e6 [Research Support, Non-U.S. Gov't]
82. M. Choi, L.K. Heilbrun, R. Venkatramanamoorthy, J.M. Lawhorn-Crews, M.M. Zalupski, and A.F. Shields Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer Am J Clin Oncol 33 3 2010 257 261
83. T. Higashi, H. Sakahara, and T. Torizuka et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET J Nucl Med 40 9 1999 1424 1433
84. M. Yoshioka, T. Sato, and T. Furuya et al. Role of positron emission tomography with 2-deoxy-2[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer J Gastroenterol 39 1 2004 50 55
85. H. Kittaka, H. Takahashi, and H. Ohigashi et al. Role of (1)(8)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer World J Surg 37 1 2013 Jan 169 178 [Research Support, Non-U.S. Gov't]
86. C. Parlak, E. Topkan, C. Onal, M. Reyhan, and U. Selek Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy Radiat Oncol 7 2012 37
87. E. Topkan, C. Parlak, A. Kotek, A.F. Yapar, and B. Pehlivan Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy BMC Gastroenterol 11 2011 123
88. H.S. Hong, M. Yun, and A. Cho et al. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm Clin Nucl Med 35 10 2010 Oct 776 779
89. G.L. Baiocchi, F. Bertagna, and F. Gheza et al. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed Ann Surg Oncol 19 11 2012 Oct 3574 3580 [Clinical Trial]
90. F. Bertagna, G. Treglia, G.L. Baiocchi, and R. Giubbini F18-FDG-PET/CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature Jpn J Radiol 31 4 2013 Apr 229 236
91. M. Saito, T. Ishihara, and M. Tada et al. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm Clin Gastroenterol Hepatol 11 2 2013 Feb 181 186
92. Y. Tomimaru, Y. Takeda, and M. Tatsumi et al. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas Oncol Rep 24 3 2010 Sep 613 620